The impact of tumor necrosis factor α inhibitors on radiographic progression in ankylosing spondylitis

Arthritis and Rheumatism

Volumn 65, Issue 10, 2013, Pages 2645-2654

  Haroon, Nigil ^a   Inman, Robert D ^a   Learch, Thomas J ^b   Weisman, Michael H ^b   Lee, Minjae ^c   Rahbar, Mohammad H ^c   Ward, Michael M ^d   Reveille, John D ^c   Gensler, Lianne S ^e  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b CEDARS SINAI MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS   (United States)

^d NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; NONSTEROID ANTIINFLAMMATORY AGENT; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADULT; ANKYLOSING SPONDYLITIS; ARTICLE; CLINICAL TRIAL; DISEASE ACTIVITY; DISEASE COURSE; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; ONSET AGE; PRIORITY JOURNAL; SEX; SMOKING; SPINE; SPINE RADIOGRAPHY;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIRHEUMATIC AGENTS; C-REACTIVE PROTEIN; COHORT STUDIES; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HLA-B27 ANTIGEN; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SPINE; SPONDYLITIS, ANKYLOSING; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84885126123     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.38070     Document Type: Article

References (32)

1. Khan MA, van der Linden SM,. Ankylosing spondylitis and other spondyloarthropathies. Rheum Dis Clin North Am 1990; 16: 551-79.
2. Revicki DA, Luo MP, Wordsworth P, Wong RL, Chen N, Davis JC Jr, et al, for the ATLAS Study Group. Adalimumab reduces pain, fatigue, and stiffness in patients with ankylosing spondylitis: results from the Adalimumab Trial Evaluating Long-Term Safety and Efficacy for Ankylosing Spondylitis (ATLAS) [published erratum appears in J Rheumatol 2011;38:788]. J Rheumatol 2008; 35: 1346-53.
3. Van der Heijde D, Dijkmans B, Geusens P, Sieper J, DeWoody K, Williamson P, et al, and the Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy Study Group. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 2005; 52: 582-91.
4. Braun J, van der Horst-Bruinsma IE, Huang F, Burgos-Vargas R, Vlahos B, Koenig AS, et al. Clinical efficacy and safety of etanercept versus sulfasalazine in patients with ankylosing spondylitis: a randomized, double-blind trial. Arthritis Rheum 2011; 63: 1543-51.
5. Inman RD, Davis JC Jr, van der Heijde D, Diekman L, Sieper J, Kim SI, et al. Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum 2008; 58: 3402-12.
6. Boonen A, vander Cruyssen B, de Vlam K, Steinfeld S, Ribbens C, Lenaerts J, et al. Spinal radiographic changes in ankylosing spondylitis: association with clinical characteristics and functional outcome. J Rheumatol 2009; 36: 1249-55.
7. Landewe R, Dougados M, Mielants H, van der Tempel H, van der Heijde D,. Physical function in ankylosing spondylitis is independently determined by both disease activity and radiographic damage of the spine. Ann Rheum Dis 2009; 68: 863-7.
8. Machado P, Landewe R, Braun J, Hermann KG, Baker D, van der Heijde D,. Both structural damage and inflammation of the spine contribute to impairment of spinal mobility in patients with ankylosing spondylitis. Ann Rheum Dis 2010; 69: 1465-70.
9. Wanders A, Landewe R, Dougados M, Mielants H, van der Linden S, van der Heijde D,. Association between radiographic damage of the spine and spinal mobility for individual patients with ankylosing spondylitis: can assessment of spinal mobility be a proxy for radiographic evaluation? Ann Rheum Dis 2005; 64: 988-94.
10. Van der Heijde D, Salonen D, Weissman BN, Landewe R, Maksymowych WP, Kupper H, et al, and the Canadian (M03-606) Study Group and the ATLAS Study Group. Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years. Arthritis Res Ther 2009; 11: R127.
11. Van der Heijde D, Landewe R, Baraliakos X, Houben H, van Tubergen A, Williamson P, et al, and the Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy Study Group. Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis. Arthritis Rheum 2008; 58: 3063-70.
12. Van der Heijde D, Landewe R, Einstein S, Ory P, Vosse D, Ni L, et al. Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. Arthritis Rheum 2008; 58: 1324-31.
13. Gran JT, Skomsvoll JF,. The outcome of ankylosing spondylitis: a study of 100 patients. Br J Rheumatol 1997; 36: 766-71.
14. Haroon N, Kim TH, Inman RD,. NSAIDs and radiographic progression in ankylosing spondylitis: bagging big game with small arms? Ann Rheum Dis 2012; 71: 1593-5.
15. Van der Linden S, Valkenburg HA, Cats A,. Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New York criteria. Arthritis Rheum 1984; 27: 361-8.
16. Creemers MC, Franssen MJ, van 't Hof MA, Gribnau FW, van de Putte LB, van Riel PL,. Assessment of outcome in ankylosing spondylitis: an extended radiographic scoring system. Ann Rheum Dis 2005; 64: 127-9.
17. Ward MM, Learch TJ, Weisman MH,. Cervical vertebral squaring in patients without spondyloarthritis [letter]. J Rheumatol 2012; 39: 1900.
18. Poddubnyy D, Haibel H, Listing J, Marker-Hermann E, Zeidler H, Braun J, et al. Baseline radiographic damage, elevated acute-phase reactant levels, and cigarette smoking status predict spinal radiographic progression in early axial spondylarthritis. Arthritis Rheum 2012; 64: 1388-98.
19. Haroon N, Maksymowych WP, Rahman P, Tsui FW, O'Shea FD, Inman RD,. Radiographic severity of ankylosing spondylitis is associated with polymorphism of the large multifunctional peptidase 2 gene in the Spondyloarthritis Research Consortium of Canada cohort. Arthritis Rheum 2012; 64: 1119-26.
20. Salaffi F, Carotti M, Garofalo G, Giuseppetti GM, Grassi W,. Radiological scoring methods for ankylosing spondylitis: a comparison between the Bath Ankylosing Spondylitis Radiology Index and the modified Stoke Ankylosing Spondylitis Spine Score. Clin Exp Rheumatol 2007; 25: 67-74.
21. Dougados M, Paternotte S, Braun J, Burgos-Vargas R, Maksymowych WP, Sieper J, et al. ASAS recommendations for collecting, analysing and reporting NSAID intake in clinical trials/epidemiological studies in axial spondyloarthritis. Ann Rheum Dis 2011; 70: 249-51.
22. Poddubnyy D, Rudwaleit M, Haibel H, Listing J, Marker-Hermann E, Zeidler H, et al. Effect of non-steroidal anti-inflammatory drugs on radiographic spinal progression in patients with axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort. Ann Rheum Dis 2012; 71: 1616-22.
23. Kaan U, Ferda O,. Evaluation of clinical activity and functional impairment in smokers with ankylosing spondylitis. Rheumatol Int 2005; 25: 357-60.
24. Averns HL, Oxtoby J, Taylor HG, Jones PW, Dziedzic K, Dawes PT,. Smoking and outcome in ankylosing spondylitis. Scand J Rheumatol 1996; 25: 138-42.
25. Ward MM, Hendrey MR, Malley JD, Learch TJ, Davis JC Jr, Reveille JD, et al. Clinical and immunogenetic prognostic factors for radiographic severity in ankylosing spondylitis. Arthritis Rheum 2009; 61: 859-66.
26. Doran MF, Brophy S, MacKay K, Taylor G, Calin A,. Predictors of longterm outcome in ankylosing spondylitis. J Rheumatol 2003; 30: 316-20.
27. Chung HY, Machado P, van der Heijde D, D'Agostino MA, Dougados M,. Smokers in early axial spondyloarthritis have earlier disease onset, more disease activity, inflammation and damage, and poorer function and health-related quality of life: results from the DESIR cohort. Ann Rheum Dis 2012; 71: 809-16.
28. Baraliakos X, Listing J, von der Recke A, Braun J,. The natural course of radiographic progression in ankylosing spondylitis: differences between sexes and appearance of characteristic radiographic features. Curr Rheumatol Rep 2011; 13: 383-7.
29. Van Tubergen A, Ramiro S, van der Heijde D, Dougados M, Mielants H, Landewe R,. Development of new syndesmophytes and bridges in ankylosing spondylitis and their predictors: a longitudinal study. Ann Rheum Dis 2012; 71: 518-23.
30. Lee W, Reveille JD, Davis JC Jr, Learch TJ, Ward MM, Weisman MH,. Are there sex differences in severity of ankylosing spondylitis? Results from the PSOAS cohort. Ann Rheum Dis 2007; 66: 633-8.
31. Wanders A, van der Heijde D, Landewe R, Behier JM, Calin A, Olivieri I, et al. Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum 2005; 52: 1756-65.
32. Boersma JW,. Retardation of ossification of the lumbar vertebral column in ankylosing spondylitis by means of phenylbutazone. Scand J Rheumatol 1976; 5: 60-4.